NASDAQ:RNAZ TransCode Therapeutics (RNAZ) Stock Price, News & Analysis $1.65 -0.07 (-4.07%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.84 +0.19 (+11.27%) As of 09/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsSEC Filings About TransCode Therapeutics Stock (NASDAQ:RNAZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TransCode Therapeutics alerts:Sign Up Key Stats Today's Range$1.65▼$2.0050-Day Range$1.60▼$8.7352-Week Range$1.58▼$20.99Volume30,776 shsAverage Volume80,517 shsMarket Capitalization$27.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview TransCode Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for the treatment of metastatic cancer. The company’s research is centered on therapies designed to target biological mechanisms involved in cancer spread while helping deliver therapeutic RNA to tumor sites. TransCode’s lead investigational product is TTX-MC138, an RNA therapeutic intended to inhibit microRNA-10b, a molecule associated with the development and progression of metastatic disease. The candidate uses the company’s TTX nanoparticle delivery platform, which is designed to transport therapeutic payloads to tumors. Based in Boston, Massachusetts, TransCode conducts research and clinical development activities primarily in the United States. Its programs remain investigational and are subject to clinical testing and regulatory review; the company’s therapies are not yet approved for general commercial use.AI Generated. May Contain Errors. Read More TransCode Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreRNAZ MarketRank™: TransCode Therapeutics scored higher than 6% of companies evaluated by MarketBeat, and ranked 872nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingTransCode Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about TransCode Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TransCode Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransCode Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransCode Therapeutics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TransCode Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.27% of the float of TransCode Therapeutics has been sold short.Short Interest Ratio / Days to CoverTransCode Therapeutics has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TransCode Therapeutics has recently increased by 48.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransCode Therapeutics does not currently pay a dividend.Dividend GrowthTransCode Therapeutics does not have a long track record of dividend growth. News and Social Media0.7 / 5News Sentiment-0.87 News SentimentTransCode Therapeutics has a news sentiment score of -0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TransCode Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RNAZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.10% of the stock of TransCode Therapeutics is held by insiders.Percentage Held by InstitutionsTransCode Therapeutics has minimal institutional ownership at this time.Read more about TransCode Therapeutics' insider trading history. Receive RNAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAZ Stock News HeadlinesTransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer TranscriptSeptember 16, 2026 | seekingalpha.comJoin Today’s Live Investor Webinar with TransCode TherapeuticsSeptember 16, 2026 | usatoday.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 20 at 1:00 AM | Paradigm Press (Ad)TransCode Therapeutics Announces Leadership TransitionSeptember 10, 2026 | prnewswire.comJoin TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic CancerSeptember 3, 2026 | usatoday.comTransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone MetastasisAugust 31, 2026 | prnewswire.comVirax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVAugust 7, 2026 | finance.yahoo.comTransCode Therapeutics, Inc.July 22, 2026 | edition.cnn.comSee More Headlines RNAZ Stock Analysis - Frequently Asked Questions How have RNAZ shares performed this year? TransCode Therapeutics' stock was trading at $6.83 at the beginning of 2026. Since then, RNAZ stock has decreased by 75.8% and is now trading at $1.65. How were TransCode Therapeutics' earnings last quarter? TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced its quarterly earnings data on Friday, August, 14th. The company reported ($7.17) earnings per share (EPS) for the quarter. When did TransCode Therapeutics' stock split? TransCode Therapeutics's stock reverse split before market open on Tuesday, January 16th 2024.The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did TransCode Therapeutics IPO? TransCode Therapeutics (RNAZ) raised $25 million in an IPO on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share. How do I buy shares of TransCode Therapeutics? Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransCode Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransCode Therapeutics investors own include Plug Power (PLUG), AMC Entertainment (AMC), Nuwellis (NUWE), ARMOUR Residential REIT (ARR), BIOLASE (BIOL) and Imperial Petroleum (IMPP). Company Calendar Last Earnings8/14/2026Today9/20/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RNAZ's financial health is in the Yellow zone, according to TradeSmith. RNAZ has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RNAZ CIK1829635 Webwww.transcodetherapeutics.com Phone(857) 301-6857FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)($52.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-875.35% Return on Assets-37.46% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.27 per share Price / Book0.15Miscellaneous Outstanding Shares16,930,000Free Float16,914,000Market Cap$27.93 million OptionableNot Optionable Beta1.16 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:RNAZ) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts